drugset / Trial / NCT06873542
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This trial employs a non-randomized, open-label, dose-escalation design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC05F01 in Chinese patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2022-07-08
- Primary completion
- 2022-12-07
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC05F01 | Unknown | 1200 mg | Oral |
| Subject | DC05F01 | Unknown | 1600 mg | Oral |
| Subject | DC05F01 | Unknown | 2100 mg | Oral |